
样式: 排序: IF: - GO 导出 标记为已读
-
Long-Read Genome Sequencing in Clinical Psychiatry: RFX3 Haploinsufficiency in a Hospitalized Adolescent With Autism, Intellectual Disability, and Behavioral Decompensation. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-09
Milad Mortazavi,Sergey Batalov,Jerica Lenberg,Corrine Blucher,Aisha Omorodion,Daniel Helbling,Lucita Van Der Kraan,Zaira Bezares-Orin,Arivudainambi Ramalingam,Matthew N Bainbridge,Jonathan Sebat,Aaron D Besterman -
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-09
Sean Esteban McCabe,Emily Pasman,Timothy E Wilens,Ty S Schepis,Vita V McCabe,Jason A Ford,John Jardine,Philip T Veliz -
Variability Rather Than Means? Harnessing the Adversary to Advance Precision Psychiatry. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Raquel E Gur,David R Roalf,Daniel H Wolf,Ruben C Gur -
Kynurenic Acid and Promotion of Activity-Dependent Synapse Elimination in Schizophrenia. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Funda Orhan,Susmita Malwade,Neda Khanlarkhani,Asimenia Gkogka,Angelika Langeder,Oscar Jungholm,Marja Koskuvi,Šárka Lehtonen,Lilly Schwieler,Kent Jardemark,Jari Tiihonen,Jari Koistinaho,Sophie Erhardt,Göran Engberg,Samudyata Samudyata,Carl M SellgrenOBJECTIVE Schizophrenia is a neurodevelopmental disorder characterized by an excessive loss of synapses. Kynurenic acid (KYNA), a neuroactive metabolite of tryptophan along the kynurenine pathway, can induce schizophrenia-related phenotypes in rodents, and clinical studies have revealed elevated KYNA levels in the CNS of individuals with schizophrenia. However, the factors that cause elevated KYNA
-
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
K N Roy Chengappa,Jessica M Gannon,Yash B Joshi -
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Lan Zhou,Iris E C Sommer,Pengyuan Yang,Lev Sikirin,Jim van Os,Richard P Bentall,Filippo Varese,Marieke J H BegemannOBJECTIVE Estimating the current association between childhood adversity and the risk of psychosis is crucial for prevention and intervention. We provided an updated synthesis of evidence from the past four decades, expanded the available data by investigating a broad array of adversity subtypes, and explored sex differences and the age of psychosis onset as relevant factors. METHODS We searched PubMed
-
Psychotic Disorders and Schizophrenia: Treatment, Risk, Brain Alterations, and Mechanisms. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Ned H Kalin -
When the Bow Breaks: Are We Ever Going to Prevent Childhood Adversity? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
C Neill Epperson -
Long-Term Antipsychotic Use and the Benefit-to-Harm Balance: More on the Risk of Relapse. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Robin Emsley -
An Update on the Use of Neuromodulation Strategies in the Treatment of Schizophrenia. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Nicholas H Neufeld,Daniel M BlumbergerThe field of neuromodulation has evolved tremendously and now includes a vast array of interventions utilizing different technologies that span electrical, magnetic, and ultrasound forms of stimulation. The evolution of interventions holds the promise of fewer adverse effects and a noninvasive approach, increasing the scale at which these interventions may be offered in hospital and community settings
-
20 Years of Aberrant Salience in Psychosis: What Have We Learned? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-26
Philip R Corlett,Kurt M FraserTwenty years ago Shitij Kapur's "Psychosis as a state of aberrant salience" captured the attention of clinicians and cognitive and behavioral neuroscientists. It has become the de facto way of talking about delusion formation in labs and clinics. Here, evidence for this theory is critically evaluated in consideration of evolving data since its publication. A particular focus is placed on its specific
-
A Call to Action: Evidence-Based Contingency Management. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-26
Carla J Rash,Michael McDonell,Tyler Erath,Sara Parent,Richard Rawson,Sarah Wattenberg -
Psychiatric Genetics in Clinical Practice: Essential Knowledge for Mental Health Professionals. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-26
Aaron D Besterman,Mohamed A Alnor,Mauricio Castaño,Lynn E DeLisi,Dorothy E Grice,Falk W Lohoff,Christel M Middeldorp,Daniel J Müller,Diego Quattrone,John Nurnberger,Erika L Nurmi,David A Ross,Takahiro Soda,Thomas G Schulze,Brett Trost,Elisabet Vilella,Chloe X Yap,Gwyneth Zai,Daniel Moreno-De-LucaOBJECTIVE The authors provide recommendations on incorporating recent advances in psychiatric genetics into clinical practice for mental health clinicians. METHOD The International Society for Psychiatric Genetics Education Committee met monthly to come to a consensus on priority topics in psychiatric genetics. Topics were then assigned to small teams of subspecialty experts to summarize the current
-
High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-26
Stephanie Lake,Conor H Murray,Brittany Henry,Liza Strong,Kendall White,Beau Kilmer,Ziva D CooperOBJECTIVE Amid continuously rising concentrations of delta-9-tetrahydrocannabinol (THC) in cannabis (i.e., potency), high-potency cannabis is a major topic in contemporary cannabis policy discussions, yet its impact on health is not well understood. The authors conducted a systematic review of observational and experimental studies examining the relationship between high-potency cannabis use and a
-
A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-19
Sonya B Norman,Matthew T Luciano,Kaitlyn E Panza,Brittany C Davis,Michelle Lyons,Brian Martis,Scott C Matthews,Abigail C Angkaw,Moira Haller,Katharine Lacefield,Arthur L Brody,Paula P Schnurr,Steven L Batki,Tracy L Simpson,Robert M AnthenelliOBJECTIVE Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur. Prolonged exposure (PE) is an effective treatment for PTSD but shows smaller effects in patients with co-occurring AUD. Topiramate may help reduce alcohol use and PTSD symptoms. This double-blind, placebo-controlled outpatient clinical trial compared 12 sessions of PE plus either topiramate or placebo
-
Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and Guideline. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-19
Victor M Tang,Scott Aaronson,Mohamed Abdelghani,Chris Baeken,Tracy Barbour,André R Brunoni,Samuel Bulteau,Linda L Carpenter,Paul E Croarkin,Zafiris J Daskalakis,Paul B Fitzgerald,F Andrew Kozel,Bernard Le Foll,Urvakhsh Meherwan Mehta,Yoshihiro Noda,Frank Padberg,Christian Plewnia,Hang Su,Philip van Eijndhoven,Eric van Exel,Iris van Oostrom,Fidel Vila-Rodriguez,Daphne Voineskos,Saydra Wilson,DanielOBJECTIVE Limited data are available to inform clinicians on how to manage concurrent substance use in the context of repetitive transcranial magnetic stimulation (rTMS) for the treatment of depressive, obsessive-compulsive, psychotic, or trauma-related disorders. The authors convened an international panel of 24 rTMS experts, representative of different geographic regions and subspecialities, and
-
Six Years After Approval of Esketamine Nasal Spray for Serious Depression: Clinical Conundrums and Unanswered Questions. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-01
Sanjay J Mathew,Nicholas Murphy -
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-01
Metten Somers,Floortje E Scheepers -
New Developments in the Treatment of Depression, OCD, and Schizophrenia. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-01
Ned H Kalin -
Beyond Feared Outcomes: Exploring Sensory Phenomena as a Novel Therapeutic Target for OCD. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-01
Dana E Díaz,Kate D Fitzgerald -
Pharmaco-Transcranial Magnetic Stimulation: Letting Mechanism Guide the Way. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-01
Joshua C Brown,Noah S Philip -
Spaced Transcranial Direct Current Stimulation for Depression: The Road Less Traveled. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-01
Andre R Brunoni,Frank Padberg -
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-01
Daniel C Javitt -
Anticholinergic Burden and Cognitive Function in Psychosis: A Systematic Review and Meta-Analysis. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-26
Valentina Mancini,Caren Latreche,Jack B Fanshawe,Ioana Varvari,Chambrez-Zita Zauchenberger,Nova McGinn,Ana Catalan,Toby Pillinger,Philip K McGuire,Robert A McCutcheonOBJECTIVE The authors synthesized evidence from studies quantifying the relationship between anticholinergic medication and cognitive function in psychosis, and additionally explored studies that investigated whether reducing anticholinergic medications affects cognitive function in individuals with psychosis. METHODS A database search was conducted in MEDLINE, Embase, and PsycINFO, from database inception
-
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-19
Alexander McGirr,Jaeden Cole,Scott B Patten,Beverly Adams -
Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-19
Jari Tiihonen,Antti Tanskanen,Marco Solmi,Jose M Rubio,Christoph U Correll,John M Kane,Heidi TaipaleOBJECTIVE It is not known what proportion of patients experience relapse in first-episode schizophrenia despite continuous dopamine D2 receptor blockade and whether breakthrough psychosis is attributable to long-term use of D2-blocking antipsychotics. Using data from a Finnish nationwide cohort, the authors sought to test the hypothesis that the incidence of breakthrough psychosis is accelerated among
-
Tobacco, Alcohol, Heroin, Binge Eating, and Behavioral Addictions. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Ned H Kalin -
Prospective Associations Between Tobacco Product Use and Mental Health and Substance Use Problems Among U.S. Adolescents and Adults. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Kevin P Conway,Emmanuella Michel,Sam Eig,Jian-Ping He,Kathleen R MerikangasOBJECTIVE The authors examined prospective associations between tobacco product use and mental health and substance use problems among U.S. adolescents and adults. METHODS Covariate-adjusted models using discrete-time survival analysis of five annual waves (2013-2014 to 2018-2019) were used to examine the links between specific tobacco product use and mental health and substance use problems among
-
Tobacco Use Is Associated With Mental Illness and Substance Use Problems-Now What? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Judith J Prochaska -
Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Andrea C King,Andrew M Fischer,John F Cursio,Nathan A Didier,Zoe Lee,Daniel J FridbergOBJECTIVE The allostasis theory states that, as addiction develops, alcohol is consumed to relieve negative affect rather than to produce positive effects. This study aimed to investigate the real-time subjective effects of alcohol in individuals with alcohol use disorder (AUD) and those prone to negative affect by virtue of having comorbid depressive disorder (DEP). METHODS Participants (N=221) completed
-
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Tom Hildebrandt,Elizabeth Martin -
Using Genetically Diverse Rats to Identify Individual Differences in Addiction-Related Behaviors and Brain Activity. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Ginevra D'Ottavio,Kenichiro Negishi,Yavin Shaham -
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Andrea H Weinberger,Marc L Steinberg -
Correcting Overestimations in Self-Harm Visit Data. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Abid Rizvi -
Correcting Overestimations in Self-Harm Visit Data: Response From Bommersbach and Colleagues. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Tanner J Bommersbach,Mark Olfson,Taeho Greg Rhee -
A Fresh Look at the Allostasis Theory of Addiction. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01
Markus Heilig -
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-29
Konstantinos N Fountoulakis,Athanasios Saitis,Alan F SchatzbergOBJECTIVE Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects. METHODS MEDLINE was searched with the keyword "esketamine" on March 24
-
Spaced Transcranial Direct Current Stimulation for Major Depression. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-29
Maxime Couture,Véronique Desbeaumes Jodoin,Emma Bousseau,Arash Sarshoghi,Michael A Nitsche,Daniel M Blumberger,Chantal Bolduc,Cory R Weissman,Lawrence G Appelbaum,Zafiris J Daskalakis,Mohsen Poorganji,Paul Lespérance,Jean-Philippe MironOBJECTIVE This study investigated spaced transcranial direct current stimulation for major depressive disorder, focusing on feasibility. METHODS In a prospective open-label study, 30 participants with major depressive disorder were enrolled to receive a 50-session transcranial direct current stimulation (tDCS) treatment over 2 weeks. The feasibility, safety, tolerability, and preliminary therapeutic
-
Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-29
Emily R Stern,Katherine A Collins,Laura B Bragdon,Goi Khia Eng,Nicolette Recchia,Barbara J Coffey,Evan Leibu,James W Murrough,Russell H Tobe,Dan V Iosifescu,Katherine E Burdick,Wayne K GoodmanOBJECTIVE Sensory phenomena (SP) are aversive sensations driving repetitive behaviors in obsessive-compulsive disorder (OCD) and Tourette's disorder that are not well addressed by standard treatments. SP are related to the functioning of an interoceptive-sensorimotor circuit that may be modulated by the 5-HT3 receptor antagonist ondansetron. The present study employed an experimental medicine approach
-
Use of Telemental Health Care by Children and Adolescents in the United States. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-15
Mark Olfson,Chandler McClellan,Samuel H Zuvekas,Melanie Wall,Carlos Blanco -
Distinct Behavioral Profiles and Neuronal Correlates of Heroin Vulnerability Versus Resiliency in a Multi-Symptomatic Model of Heroin Use Disorder in Rats. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-15
Brittany N Kuhn,Nazzareno Cannella,Ayteria D Crow,Veronica Lunerti,Arkobrato Gupta,Stephen J Walterhouse,Carter Allen,Reda M Chalhoub,Eric Dereschewitz,Analyse T Roberts,Mackenzie Cockerham,Angela Beeson,Rusty W Nall,Abraham A Palmer,Gary Hardiman,Leah C Solberg Woods,Dongjun Chung,Roberto Ciccocioppo,Peter W KalivasOBJECTIVE The behavioral and diagnostic heterogeneity within the opioid use disorder (OUD) diagnosis is not readily captured in current animal models, limiting the translational relevance of the mechanistic research that is conducted in experimental animals. The authors hypothesized that a nonlinear clustering of OUD-like behavioral traits would capture population heterogeneity and yield subpopulations
-
Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-15
Marjorie R Levinstein,Reece C Budinich,Jordi Bonaventura,Alan F Schatzberg,Carlos A Zarate,Michael MichaelidesKetamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders such
-
Five-Year Outcomes of a School-Based Personality-Focused Prevention Program on Adolescent Substance Use Disorder: A Cluster Randomized Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-15
Patricia Conrod,Sherry H Stewart,Jean Seguin,Robert Pihl,Benoit Masse,Sean Spinney,Samantha LynchOBJECTIVE Rates of substance use disorders (SUDs) remain significantly above national targets for health promotion and disease prevention in Canada and the United States. This study investigated the 5-year SUD outcomes following a selective drug and alcohol prevention program targeting personality risk factors for adolescent substance misuse. METHODS The Co-Venture trial is a cluster randomized trial
-
Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Maha N Mian,Michael T Dinh,Allison R Coker,Jennifer M Mitchell,Brian T Anderson -
Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Broc A Pagni,Richard J Zeifman,Sarah E Mennenga,Brennan M Carrithers,Noam Goldway,Snehal Bhatt,Kelley C O'Donnell,Stephen Ross,Michael P BogenschutzOBJECTIVE Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate
-
Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Sharmin Ghaznavi,Jeremy N Ruskin,Stephen J Haggerty,Franklin King,Jerrold F RosenbaumThe last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks. Indeed, when substances with therapeutic potential are scrutinized over
-
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Roger S McIntyre,Angela T H Kwan,Rodrigo B Mansur,Albino J Oliveira-Maia,Kayla M Teopiz,Vladimir Maletic,Trisha Suppes,Stephen M Stahl,Joshua D RosenblatDuring the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder. Preliminary
-
Psychedelics in Psychiatry: Oh, What A Trip! Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Gregory A Fonzo,Charles B Nemeroff,Ned Kalin -
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Scott T Aaronson,Andrew van der Vaart,Tammy Miller,Jeffrey LaPratt,Kimberly Swartz,Audrey Shoultz,Margo Lauterbach,Trisha Suppes,Harold A SackeimOBJECTIVE Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of this study was to document the safety and efficacy of psilocybin in patients with severe TRD. METHODS This was a 12-week, open-label trial conducted at Sheppard Pratt Hospital.
-
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Aaron S Wolfgang,Vetisha L McClair,Paula P Schnurr,Paul E Holtzheimer,Josh D Woolley,Christopher S Stauffer,R Cameron Wolf,Leith J States,David M Benedek,Vincent F Capaldi,John Bradley,Matthew A Fuller,Miriam J Smyth,Eric D A Hermes,Wendy Tenhula,Ilse R Wiechers -
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Johannes G Ramaekers,Johannes T Reckweg,Natasha L MasonUnlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an intense but
-
Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Namik Kirlić,Molly Lennard-Jones,Merve Atli,Ekaterina Malievskaia,Nadav L Modlin,Stephanie Knatz Peck,Alice Gaillard,Guy M Goodwin,Don KoelpinThe psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a framework is to support a safe and meaningful psilocybin experience. It also enables future research on the facets of psychological support and/or psychotherapy
-
Psilocybin: From Psychiatric Pariah to Perceived Panacea. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Gregory A Fonzo,Aaron S Wolfgang,Bryan R Barksdale,John H Krystal,Linda L Carpenter,Nina V Kraguljac,Adrienne Grzenda,William M McDonald,Alik S Widge,Carolyn I Rodriguez,Charles B NemeroffOBJECTIVE The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors. METHODS PubMed was searched for English-language articles from January 1998 to November 2023, using the search term "psilocybin." A total of 1,449 articles were
-
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
Kelley C O'Donnell,Jim Grigsby,Charles S Grob -
Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01
David E Olson -
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-11
Carlos M Grilo,Valentina Ivezaj,Cenk Tek,Sydney Yurkow,Ashley A Wiedemann,Ralitza GueorguievaOBJECTIVE Binge-eating disorder (BED) is a prevalent, costly public health problem associated with serious functional impairments and heightened rates of psychiatric and medical comorbidities. Few evidence-based treatments are currently available for BED. We tested the effectiveness of cognitive-behavioral therapy (CBT), lisdexamfetamine (LDX), and combined CBT+LDX, for BED comorbid with obesity. METHODS
-
Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-11
George Kypriotakis,Paul M Cinciripini,Charles E Green,David Lawrence,Robert M Anthenelli,Jennifer A Minnix,Diane Beneventi,Chad Morris,Maher Karam-Hage,Janice A BlalockOBJECTIVE The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD). METHODS This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current
-
Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-11
Matthias Brand,Stephanie Antons,Beata Bőthe,Zsolt Demetrovics,Naomi A Fineberg,Susana Jimenez-Murcia,Daniel L King,Gemma Mestre-Bach,Tania Moretta,Astrid Müller,Elisa Wegmann,Marc N PotenzaGambling disorder is the only behavioral addiction recognized as a clinical disorder in DSM-5, and Internet gaming disorder is included as a condition requiring further research. ICD-11 categorizes gambling and gaming disorders as disorders due to addictive behaviors. Additional behavioral addictions may include compulsive sexual behavior disorder, compulsive buying-shopping disorder, and problematic
-
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-11
William P Horan,Colin Sauder,Philip D Harvey,Ian S Ramsay,Samantha E Yohn,Richard S E Keefe,Vicki G Davis,Steven M Paul,Stephen K BrannanOBJECTIVE Xanomeline and trospium chloride (formerly known as KarXT), a novel M1/M4 muscarinic receptor agonist, demonstrated efficacy across phase 2 and 3 trials as monotherapy for the treatment of inpatients with acute schizophrenia on the Positive and Negative Syndrome Scale total score primary endpoint. In the phase 2 trial, xanomeline/trospium improved performance on a cognitive outcome measure
-
The Importance and Limitations of Null Findings. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01
Dan J Stein,Jack van Honk,Paul M Thompson